Psychedelic Stock News

MINDCURE Announces Listing of Warrants

Mind Cure has listed the warrants for trading from its recent financing. Warrants are valid until February 10, 2026, at an exercise price of CAD$0.80.

TSI EDITOR | 2021-02-11

Countdown to Psychedelic Stock Rally, Part 2: Sector-Wide Catalysts

A number of potential sector-wide catalysts for psychedelic stocks are already present or rapidly approaching.

TSI EDITOR | 2021-02-11

Mind Cure Announces Closing of $23 Million Bought Deal Offering Including Full Exercise of Over-Allotment Option

Mind Cure closes on a CAD$23 million bought deal financing, after the full over-allotment was exercised.

TSI EDITOR | 2021-02-10

Field Trip Health Ltd. Announces Official Opening of Psychedelic Research and Cultivation Facility in Jamaica

Field Trip opens a psychedelic research facility in Jamaica, in partnership with University of the West Indies.

TSI EDITOR | 2021-02-09

Countdown to Psychedelic Stock Rally, Part 1: Individual Drivers

After a torrid rally near the end of 2020, psychedelic drug stocks have been in a holding pattern. Here is why lift-off could occur at any time.

TSI EDITOR | 2021-02-09

Tryp Therapeutics Announces Strategic Investment of $2,000,000

Tryp Therapeutics announces a CAD$2.0 private placement at a unit price of CAD$0.60

TSI EDITOR | 2021-02-05

Mindset Files Multiple Final Patent Applications on Its Novel Psilocybin-Inspired Compounds

Mindset has filed multiple patent applications regarding "both novel prodrug and deuterated derivatives of psilocybin".

TSI EDITOR | 2021-02-05

ATAI IPO Strategy: Load Up On OTHER Stocks First

ATAI Life Sciences is set to become the new industry leader among psychedelic stocks. But it may not be the best OPPORTUNITY for investors when trading begins.

TSI EDITOR | 2021-02-05